232 related articles for article (PubMed ID: 36052255)
1. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis.
Yang F; Wang Y; Tang L; Mansfield AS; Adjei AA; Leventakos K; Duma N; Wei J; Wang L; Liu B; Molina JR
Front Oncol; 2022; 12():955440. PubMed ID: 36052255
[TBL] [Abstract][Full Text] [Related]
2. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
3. Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Zhang N; Zhang J; Wang G; He X; Mi Y; Cao Y; Yu X
Front Oncol; 2022; 12():795933. PubMed ID: 35223476
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
5. Relationship between Patients' Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Hu X; Liu Y; He Y; Wang Z; Zhang H; Yang W; Lu J
J Oncol; 2022; 2022():3601942. PubMed ID: 35646119
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
Front Immunol; 2021; 12():731546. PubMed ID: 34484242
[TBL] [Abstract][Full Text] [Related]
7. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
Yang F; Markovic SN; Molina JR; Halfdanarson TR; Pagliaro LC; Chintakuntlawar AV; Li R; Wei J; Wang L; Liu B; Nowakowski GS; Wang ML; Wang Y
JAMA Netw Open; 2020 Aug; 3(8):e2012534. PubMed ID: 32766800
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer.
Wang S; Hao J; Wang H; Fang Y; Tan L
Oncoimmunology; 2018; 7(8):e1457600. PubMed ID: 30221052
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
[TBL] [Abstract][Full Text] [Related]
10. The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis.
Dai L; Jin B; Liu T; Chen J; Li G; Dang J
EClinicalMedicine; 2021 Aug; 38():100990. PubMed ID: 34505024
[TBL] [Abstract][Full Text] [Related]
11. Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis.
Li F; Zhai S; Lv Z; Yuan L; Wang S; Jin D; Yi H; Fu L; Mao Y
Front Oncol; 2022; 12():968517. PubMed ID: 36439448
[TBL] [Abstract][Full Text] [Related]
12. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Yang Y; Luo H; Zheng XL; Ge H
Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281
[TBL] [Abstract][Full Text] [Related]
13. First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis.
Liu T; Ding S; Dang J; Wang H; Chen J; Li G
J Thorac Dis; 2019 Jul; 11(7):2899-2912. PubMed ID: 31463119
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis.
Yang K; Li J; Bai C; Sun Z; Zhao L
Front Oncol; 2020; 10():1098. PubMed ID: 32733805
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.
Shi Y; Chen W; Li C; Zhang Y; Bo M; Qi S; Li G
Ann Palliat Med; 2021 Mar; 10(3):2766-2775. PubMed ID: 33549014
[TBL] [Abstract][Full Text] [Related]
16. The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Xu Y; Wang Q; Xie J; Chen M; Liu H; Zhan P; Lv T; Song Y
Front Oncol; 2021; 11():732214. PubMed ID: 34557415
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis.
Kundel Y; Sternschuss M; Moore A; Perl G; Brenner B; Goldvaser H
Cancer Med; 2020 Oct; 9(20):7613-7625. PubMed ID: 32869544
[TBL] [Abstract][Full Text] [Related]
18. Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis.
Xia H; Zhang W; Zhang Y; Shang X; Liu Y; Wang X
Front Oncol; 2022; 12():978069. PubMed ID: 36330494
[TBL] [Abstract][Full Text] [Related]
19. Smoking history and the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
Chen DL; Li QY; Tan QY
J Thorac Dis; 2021 Jan; 13(1):220-231. PubMed ID: 33569202
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
Raphael J; Batra A; Boldt G; Shah PS; Blanchette P; Rodrigues G; Vincent MD
Clin Lung Cancer; 2020 Mar; 21(2):106-113.e5. PubMed ID: 31992521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
